Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer

Abstract

Abstract:

ObjectiveTo explore and analyze the value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer.MethodsA total of 83 patients diagnosed with colorectal cancer by pathological tissue admitted to Huangshi Hospital of Traditional Chinese Medicine of Hubei Province from October 2019 to October 2020 were selected as the observation group， and 50 healthy volunteers who underwent physical examinations during the same period were selected as the control group. The levels of miR-194 in peripheral blood and miR-143 in feces were detected by fluorescence quantitative PCR. The level difference between the two groups and their correlations with clinicopathological parameters of patients with colorectal cancer were analyzed. Receiver operating characteristic （ROC） curve was drawn based on peripheral blood miR-194 and fecal miR-143 to evaluate their value for clinical screening of colorectal cancer.ResultsThe level of miR-194 in peripheral blood of the observation group was significantly higher than that of the control group （1.91±0.34vs.0.76±0.23）， while the level of fecal miR-143 in the observation group being significantly lower than that of the control group （1.85±0.43vs.2.48±0.62）， with statistically significant differences （t=21.16，P<0.001；t=6.91，P<0.001）. Age of patients with colorectal cancer （t=0.83，P=0.408；t=1.17，P=0.244）， TNM stage （t=1.03，P=0.307；t=0.11，P=0.909）， lymphatic metastasis （t=0.37，P=0.711；t=1.85，P=0.068）， distant metastasis （t=0.41，P=0.683；t=1.72，P=0.089） were not correlated with the levels of peripheral blood miR-194 and fecal miR-143. When the cut-off value of miR-194 in peripheral blood was 1.82， the area under the ROC curve for the diagnosis of colorectal cancer was 0.76， and the diagnostic sensitivity and specificity were 79.38% and 74.29%， respectively. When the cut-off value of fecal miR-143 was 2.16， the area under the ROC curve for the diagnosis of colorectal cancer was 0.71. At this time， the diagnostic sensitivity and specificity were 76.54% and 73.61%， respectively. The area under ROC curve of combined detection for colorectal cancer was 0.81， and the diagnostic sensitivity and specificity were 83.46% and 75.43%， respectively.ConclusionPeripheral blood miR-194 is highly expressed in colorectal cancer patients， and fecal miR-143 is low in colorectal cancer patients. The combined detection of the two has a high sensitivity for early diagnosis of colorectal cancer， which can provide important reference basis for early diagnosis of colorectal cancer and has high clinical application value.

Key words:Colorectal neoplasms,Peripheral blood miR-194,Fecal miR-143,Screening,Clinical value

Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.

Figures/Tables4

组别	性别		年龄（岁）
观察组（n=83）	51（61.45）	32（38.55）		38（45.78）	45（54.22）
对照组（n=50）	29（58.00）	21（42.00）		26（52.00）	24（48.00）
χ²值	0.16		0.48
P值	0.694		0.487

组别	外周血miR-194水平	粪便miR-143水平
观察组（n=83）	1.91±0.34	1.85±0.43
对照组（n=50）	0.76±0.23	2.48±0.62
t值	21.16	6.91
P值	<0.001	<0.001

临床病理特征	例数	外周血miR-194	t值	P值	粪便miR-143	t值	P值
年龄（岁）
≥65	38	1.75±0.42	0.83	0.408	1.86±0.32	1.17	0.244
<65	45	1.83±0.45	0.83	0.408	1.95±0.37	1.17	0.244
TNM分期
Ⅰ~Ⅱ期	27	2.01±0.52	1.03	0.307	1.96±0.38	0.11	0.909
Ⅲ~Ⅳ期	56	1.89±0.46	1.03	0.307	2.11±0.42	0.11	0.909
淋巴结转移
有	32	1.87±0.47	0.37	0.711	1.92±0.43	1.85	0.068
无	51	1.91±0.48	0.37	0.711	1.78±0.26	1.85	0.068
远处转移
有	24	1.86±0.49	0.41	0.683	2.12±0.47	1.72	0.089
无	59	1.91±0.51	0.41	0.683	1.93±0.45	1.72	0.089

References24

[1]	潘辉, 黄琰璎, 王国新, 等. 粪便基因SDC2和BMP3甲基化联合检测在结直肠癌筛查中的价值[J]. 中国医药导报, 2020, 17(11): 15-19.
[2]	Zhou R, Qiu P, Wang H, et al. Identification of microRNA-16-5p and microRNA-21-5p in feces as potential noninvasive biomarkers for inflammatory bowel disease[J]. Aging (Albany NY), 2021, 13(3): 4634-4646. DOI: 10.18632/aging.202428. doi:10.18632/aging.202428
[3]	Moody L, Dvoretskiy S, An R, et al. The efficacy of miR-20a as a diagnostic and prognostic biomarker for colorectal cancer: a systematic review and meta-analysis[J]. Cancers (Basel), 2019, 11(8): 1111. DOI: 10.3390/cancers11081111. doi:10.3390/cancers11081111
[4]	邵书先, 沈忠, 张秀峰, 等. 粪便多基因联合检测在结直肠癌早期筛查中的应用[J]. 中华全科医学, 2020, 18(11): 1819-1822. DOI: 10.16766/j.cnki.issn.1674-4152.001627. doi:10.16766/j.cnki.issn.1674-4152.001627
[5]	Yau TO, Tang CM, Harriss EK, et al. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: a meta-analysis[J]. Sci Rep, 2019, 9(1): 9491. DOI: 10.1038/s41598-019-45570-9. doi:10.1038/s41598-019-45570-9pmid:31263200
[6]	Duran-Sanchon S, Moreno L, Augé JM, et al. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer[J]. Gastroenterology, 2020, 158(4): 947-957.e4. DOI: 10.1053/j.gastro.2019.10.005. doi:S0016-5085(19)41439-Xpmid:31622624
[7]	朱富强, 唐亚萍, 彭树松, 等. 粪便中miR-31的表达对结直肠癌早期筛查的价值[J]. 中国医师杂志, 2019, 21(8): 1232-1233. DOI: 10.3760/cma.j.issn.1008-1372.2019.08.032. doi:10.3760/cma.j.issn.1008-1372.2019.08.032
[8]	Duran-Sanchon S, Moreno L, Gómez-Matas J, et al. Fecal microRNA-based algorithm increases effectiveness of fecal immunochemical test-based screening for colorectal cancer[J]. Clin Gastroenterol Hepatol, 2021, 19(2): 323-330.e1. DOI: 10.1016/j.cgh.2020.02.043. doi:10.1016/j.cgh.2020.02.043
[9]	Brînzan C, Aşchie M, Cozaru G, et al. The diagnostic value of miR-92a, -143, and -145 expression levels in patients with colorectal adenocarcinoma from Romania[J]. Medicine (Baltimore), 2020, 99(35): e21895. DOI: 10.1097/MD.0000000000021895. doi:10.1097/MD.0000000000021895
[10]	冷晓旭, 房静远. 粪便标志物DNA和RNA筛查结直肠癌特性分析[J]. 中华医学杂志, 2020, 100(42): 3373-3376. DOI: 10.3760/cma.j.cn112137-20200228-00507. doi:10.3760/cma.j.cn112137-20200228-00507
[11]	Ardila HJ, Sanabria-Salas MC, Meneses X, et al. Circulating miR-141-3p, miR-143-3p and miR-200c-3p are differentially expressed in colorectal cancer and advanced adenomas[J]. Mol Clin Oncol, 2019, 11(2): 201-207. DOI: 10.3892/mco.2019.1876. doi:10.3892/mco.2019.1876pmid:31316774
[12]	Sahami-Fard MH, Kheirandish S, Sheikhha MH. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance[J]. Cancer Biomark, 2019, 24(3): 291-297. DOI: 10.3233/CBM-182171. doi:10.3233/CBM-182171pmid:30883340
[13]	张江国, 汪之沫. 粪便多靶点DNA和miR-135b表达联合检测诊断结直肠癌的价值[J]. 山东医药, 2019, 59(19): 60-63. DOI: 10.3969/j.issn.1002-266X.2019.19.016. doi:10.3969/j.issn.1002-266X.2019.19.016
[14]	Yang Q, Zheng W, Shen Z, et al. MicroRNA binding site polymorphisms of the long-chain noncoding RNA MALAT1 are associated with risk and prognosis of colorectal cancer in Chinese Han population[J]. Genet Test Mol Biomarkers, 2020, 24(5): 239-248. DOI: 10.1089/gtmb.2020.0013. doi:10.1089/gtmb.2020.0013
[15]	张肖丽, 张月晓, 李萍, 等. 结肠癌患者血清miRNA表达意义及与肠道菌群失调关联性[J]. 中国微生态学杂志, 2022, 34(1): 46-51. DOI: 10.13381/j.cnki.cjm.202201008. doi:10.13381/j.cnki.cjm.202201008
[16]	Feng Y, Xu Y, Gao Y, et al. A novel lncRNA SOX2OT promotes the malignancy of human colorectal cancer by interacting with miR-194-5p/SOX5 axis[J]. Cell Death Dis, 2021, 12(5): 499. DOI: 10.1038/s41419-021-03756-y. doi:10.1038/s41419-021-03756-ypmid:33993197
[17]	Wu S, Sun H, Wang Y, et al. MALAT1 rs664589 polymorphism inhibits binding to miR-194-5p, contributing to colorectal cancer risk, growth, and metastasis[J]. Cancer Res, 2019, 79(20): 5432-5441. DOI: 10.1158/0008-5472.CAN-19-0773. doi:10.1158/0008-5472.CAN-19-0773pmid:31311811
[18]	Li G, Wang Q, Li Z, et al. Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer[J]. Rev Esp Enferm Dig, 2020, 112(11): 832-837. DOI: 10.17235/reed.2020.6801/2019. doi:10.17235/reed.2020.6801/2019pmid:33054296
[19]	连戴政, 刘雅洁. 粪便miRNA标志物在结直肠癌筛选和诊断中的应用研究进展[J]. 肿瘤学杂志, 2019, 25(4): 310-314. DOI: 10.11735/j.issn.1671-170X.2019.04.B005. doi:10.11735/j.issn.1671-170X.2019.04.B005
[20]	Peng Q, Shen Y, Zhao P, et al. Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer[J]. BMC Cancer, 2020, 20(1): 506. DOI: 10.1186/s12885-020-06863-9. doi:10.1186/s12885-020-06863-9pmid:32493303
[21]	Choi HH, Cho YS, Choi JH, et al. Stool-based miR-92a and miR-144* as noninvasive biomarkers for colorectal cancer screening[J]. Oncology, 2019, 97(3): 173-179. DOI: 10.1159/000500639. doi:10.1159/000500639pmid:31216561
[22]	王胜, 吴英光, 何孟胜. 血清miR-200a、miR-190联合检测在结直肠癌诊断及预后评估中的应用价值[J]. 国际消化病杂志, 2019, 39(4): 286-290. DOI: 10.3969/j.issn.1673-534X.2019.04.011. doi:10.3969/j.issn.1673-534X.2019.04.011
[23]	Xu M, Chen X, Lin K, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer[J]. J Hematol Oncol, 2019, 12(1): 3. DOI: 10.1186/s13045-018-0690-5. doi:10.1186/s13045-018-0690-5
[24]	Xu K, Zhan Y, Yuan Z, et al. Hypoxia induces drug resistance in colorectal cancer through the HIF-1α/miR-338-5p/IL-6 feedback loop[J]. Mol Ther, 2019, 27(10): 1810-1824. DOI: 10.1016/j.ymthe.2019.05.017. doi:S1525-0016(19)30264-3pmid:31208913